Black Diamond Therapeutics, Inc. BDTX · Stock Open Black Diamond Therapeutics, Inc. in new tab
Black Diamond Therapeutics, Inc. Analysis (BDTX)
Is Black Diamond Therapeutics, Inc. a good investment? Black Diamond Therapeutics, Inc. (BDTX) is currently trading at 1.74 USD. Market analysts have a consensus price target of 9.86 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 6.67. This relatively low multiple may signal that Black Diamond Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Black Diamond Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.09.
Investor FAQ
Does Black Diamond Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Black Diamond Therapeutics, Inc.?
Black Diamond Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -0.77.
Company Profile
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Community Discussion